Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.0002730897METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS
RU 26.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2020121770 Applicant Inventor Костин Никита Николаевич (RU)
FIELD: medicine. SUBSTANCE: invention refers to medicine and molecular biology. Essence of the invention is that for the purpose of detecting antibodies belonging to different classes of immunoglobulins, in blood serum or plasma of patients with COVID-19 or infected with said virus, uses a complex of antigenic recombinant proteins (RBD-SD1 and NTD fragments of spike-protein of SARS-CoV-2 virus, as well as nucleoprotein of SARS-CoV-2 virus, obtained on the basis of artificially synthesized genetic structures in plasmid DHFRControlTemplate, incorporated into strain BL21 (DE3) E.coli. Target recombinant proteins are sorbed in the pits of the folding polystyrene microplates, based on which the test system is formed, including four sets of reagents for both total and separate determination of IgM-, IgG-, IgA-antibodies to SARS-CoV-2 in laboratory diagnostics and clinical-epidemiological monitoring of COVID-19. Invention can be used for producing test systems for serological diagnosis of COVID-19 in order to assess the humoral immune response in infected individuals and epidemiological characteristics of the infectious process in the population, and in the future – to determine the effectiveness of vaccination and immunotherapy when obtaining and implementing the corresponding therapeutic and preventive preparations against SARS-CoV-2. EFFECT: invention provides complete and comprehensive assessment of the immune response to SARS-CoV-2. 10 cl, 5 dwg, 1 tbl, 3 annexes
2.111560054抑制新型冠状病毒感染的多肽及其筛选方法
CN 21.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010550481.9 Applicant 哈尔滨吉象隆生物技术有限公司 Inventor 冷国庆
本发明公开了抑制新型冠状病毒感染的多肽及其筛选方法。属于生物医药技术领域。筛选方法包括获得新型冠状病毒SARS‑CoV‑2的S蛋白基因序列;确定新型冠状病毒SARS‑CoV‑2的S蛋白区域的HR1区域和HR2区域;选取HR2区域30~36个氨基酸组成的天然肽段作为抑制新型冠状病毒感染的多肽;在所述天然肽段的基础上通过定点突变设计谷氨酸‑赖氨酸或谷氨酸‑精氨酸对形成多肽链内盐桥。与现有技术相比,本发明取得的有益效果为:本发明公开了抑制新型冠状病毒感染的多肽,能与HR1P形成稳定的6‑HB螺旋结构,具有抑制新型冠状病毒感染侵入细胞的能力。
3.111560354重组新型冠状病毒及其制备方法和应用
CN 21.08.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No 202010439738.3 Applicant 中国人民解放军总医院第五医学中心 Inventor 杨鹏辉
本发明公开了重组新型冠状病毒及其制备方法和应用。本发明首先公开了重组病毒,该重组病毒的流感病毒的NS基因、流感病毒的HA基因和流感病毒的NA基因中任一种基因被替换。本发明进一步公开了上述重组病毒在制备预防和/或治疗流感病毒和/或SARS‑CoV‑2引起的疾病的产品中的应用。本发明从基因水平对SARS‑CoV‑2抗原表位和流感病毒基因组进行操作,基于RG技术制备流感病毒为载体的重组SARS‑CoV‑2疫苗株,解决了SARS‑CoV‑2疫苗短缺难题,将是冠状病毒疫苗领域的新里程碑,且SARS‑CoV‑2嵌合疫苗可以保护更多人群免受流感病毒和SARS‑CoV‑2之害。
4.111548396一种新型冠状病毒T细胞抗原表位肽、pMHC及其制备和应用
CN 18.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010306192.4 Applicant 暨南大学 Inventor 陈国兵
本发明公开了一种新型冠状病毒T细胞抗原表位肽、pMHC及其制备和应用。所述新型冠状病毒T细胞抗原表位肽,其氨基酸序列如SEQ IDNO:1~9任一所示。本发明发现了9种新型冠状病毒T细胞抗原表位肽,并利用其制备得到了pMHC复合物单聚体,进一步制备得到pMHC复合物多聚体,其可以用于新型冠状病毒感染康复者外周血内抗原特异性T细胞的检测,并用于体外的T细胞活化实验,这些新型冠状病毒T细胞抗原表位肽可以应用到新型冠状病毒相关的免疫检测中。
5.111533790基于马赛克策略的冠状病毒抗原的构建方法及其应用
CN 14.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010387460.X Applicant 中山大学 Inventor 孙彩军
本发明提供了基于马赛克策略的冠状病毒抗原的构建方法及其应用,所述方法包括:(1)对人冠状病毒的天然结构蛋白进行分析,获取天然结构蛋白上存在的细胞毒性T淋巴细胞表位;(2)采用马赛克策略对人冠状病毒的结构蛋白进行分析,去除在天然结构蛋白中出现次数低的罕见表位后,获得由短肽组装形成的冠状病毒抗原。本发明基于人工智能算法对所有已知的CoV基因组序列进行大数据分析,基于马赛克策略设计新型抗原序列;新型抗原覆盖了所有已知的7种HCoVs上的天然S、M、N、E蛋白的大部分CTL表位,并与天然蛋白具有很好的结构相似性,在制备冠状病毒通用疫苗方面具有潜在的应用前景和价值。
6.WO/2020/161107NOVEL FISH CORONAVIRUS
WO 13.08.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/EP2020/052688 Applicant PHARMAQ AS Inventor NYLUND, Stian
The invention relates to a novel fish virus, indicated to be a Coronavirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.
7.3693465NOVEL FISH CORONAVIRUS
EP 12.08.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 19155627 Applicant PHARMAQ AS Inventor NYLUND STIAN
The invention relates to a novel fish virus, indicated to be a Coronavirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.
8.111518175SARS-COV-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
CN 11.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010392553.1 Applicant 广州派真生物技术有限公司 Inventor 周泽鑫
本发明公开了SARS‑COV‑2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用,所述的抗原多肽序列如SEQ.ID.NO.1和SEQ.ID.NO.2所示。所述的重组腺相关病毒是将将pHelper、pRep2Cap5和抗原多肽的表达载体共孵育,在转染试剂聚乙烯亚胺存在的条件下转染细胞,培育细胞后,经过裂解和纯化,得到含有重组腺相关病毒的纯化液。本发明的重组腺相关病毒在体内递送表达产生融合抗原多肽,诱导产生血清中和抗体,对SARS‑COV‑2新冠病毒具有中和效价,并持续表达,可用于对人进行针对COVID‑19新冠肺炎的免疫接种。
9.111518176一种用于新型冠状病毒抗体双抗原夹心检测的配对抗原、检测试纸及其制备方法
CN 11.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010637857.X Applicant 北京金智准科技有限公司 Inventor 陈蕾
本发明提供一种用于新型冠状病毒抗体双抗原夹心检测的配对抗原、检测试纸及其制备方法,配对抗原包括捕获抗原和检测抗原;捕获抗原和检测抗原相同或不同的选自NP1抗原、NP2抗原和NP抗原;NP1抗原具有如SEQ ID No.1所示的氨基酸序列;NP2抗原具有如SEQ ID No.2所示的氨基酸序列;NP抗原具有如SEQ ID No.3所示的氨基酸序列。该配对抗原及检测试纸用于双抗原夹心法检测血清总抗体,经验证,采用该配对抗原比单独或联合检测IgM、IgG抗体的方法具有更低的漏检、错检可能性和更高的灵敏度,且还可检测除人以外的其他动物种属的血液样本,用于兽类新型冠状病毒抗体的筛查和检测,适用范围广。
10.111505286一种新型冠状病毒特异性抗体双抗原夹心ELISA检测试剂盒及其制备方法
CN 07.08.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 202010347899.X Applicant 郑州伊美诺生物技术有限公司 Inventor 张晓雷
本发明涉及生物技术领域,公开了一种新型冠状病毒特异性抗体双抗原夹心ELISA检测试剂盒及其制备方法。本发明所述试剂盒包括包被有新型冠状病毒SARS‑CoV‑2的NP抗原和S1抗原的酶联板,以及酶标记的新型冠状病毒SARS‑CoV‑2的NP抗原和S1抗原。本发明采用基因工程表达的经糖蛋白后修饰的S1蛋白以及NP蛋白,共同作为抗原建立了基于双抗原夹心的ELISA检测试剂盒,由于血清不需要稀释,灵敏度较间接ELISA高;而且双抗原夹心无需使用酶标二抗,因此试剂的特异性也高于ELISA间接法。本发明试剂盒可以快速、准确地进行SARS‑CoV‑2病毒感染后的确诊,提高检出率和正确率。